The neuronal cyclin-dependent kinase p35/cdk5 comprises a catalytic subunit (cdk5) and an activator subunit (p35). To identify novel p35/cdk5 substrates, we utilized the yeast two-hybrid system to screen for human p35 binding partners. From one such screen, we identified beta -catenin as an interacting protein. Confirmation that p35 binds to beta -catenin was obtained by using glutathione S-transferase (GST)-beta -catenin fusion proteins that interacted with both endogenous and transfected p35, and by showing that beta -catenin was present in p35 immunoprecipitates. p35 and beta -catenin also displayed overlapping subcellular distribution patterns in cells including neurons. Finally, we demonstrated that p35/cdk5 phosphorylates beta -catenin. beta -catenin also binds to presenilin-1 and altered beta -catenin/presenilin-1 interactions may be mechanistic in Alzheimer's disease (AD). Abnormal p35/cdk5 activity has also been suggested to contribute to AD. We therefore investigated how modulation of p35/cdk5 activity influenced beta -catenin/presenilin-1 interactions. Inhibition of p35/cdk5 with roscovitine did not alter the steady state levels of either beta -catenin or presenilin-1 but reduced the amount of presenilin-1 bound to beta -catenin. Thus, p35/cdk5 binds and phosphorylates beta -catenin and regulates its binding to presenilin-1. The findings reported here therefore provide a novel molecular framework to connect p35/cdk5 with beta -catenin and presenilin-1 in AD.
No takes yet. Share an insight, caveat, or question.
Kesavapany et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: